Gyre Therapeutics Inc. (GYRE)vsVertex Pharmaceuticals Inc (VRTX)
GYRE
Gyre Therapeutics Inc.
$6.29
-4.30%
HEALTHCARE · Cap: $606.43M
VRTX
Vertex Pharmaceuticals Inc
$499.65
+1.69%
HEALTHCARE · Cap: $124.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 10338% more annual revenue ($12.22B vs $117.05M). VRTX leads profitability with a 35.5% profit margin vs -5.4%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
GYRE
Avoid25
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GYRE.
Margin of Safety
+48.3%
Fair Value
$949.55
Current Price
$499.65
$449.90 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 166.2% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
2.1% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -6.2% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GYRE
The strongest argument for GYRE centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : GYRE
The primary concerns for GYRE are Revenue Growth, Market Cap, Piotroski F-Score.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
GYRE profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
GYRE carries more volatility with a beta of 4.92 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 25/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gyre Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Gyre Therapeutics Inc. is an innovative biopharmaceutical company dedicated to advancing therapies for rare and complex diseases through its proprietary platform, which integrates gene therapy and precision medicine. The company boasts a promising pipeline focused on addressing significant unmet medical needs and improving patient outcomes. With a strong commitment to scientific excellence and strategic collaborations, Gyre is strategically positioned for impactful growth in the biopharmaceutical landscape. As it continues to enhance its research and development initiatives, Gyre stands to transform treatment paradigms for patients facing challenging health conditions.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?